Levosimendan in Europe and China: An Appraisal of Evidence and Context.

Although the percentage of patients who died or experienced worsening HF at 14 days was lower and the percentage of patients with myocardial ischaemia was higher in the levosimendan group, the differences did not reach statistical significance.[ 41 ] Overall, the percentage of patients meeting the primary composite endpoint criteria at 14 days was lower, albeit not significantly, with levosimendan (21.2% versus 26.2%).[ 41 ] At 6 months, the non-significant trends for death and worsening HF were supplemented by a significant trend for a lower incidence of MI in the levosimendan group between 14 days and 6 months (3.8% versus 13.8%; HR 0.261; p=0.036).[ 41 ] As a result, there was a significant treatment effect of levosimendan on the composite primary endpoint (43.7% versus 62.5%; HR 0.636; 95% CI [0.413–0.981]; p=0.041; Figu

also in 8,748 other papers

Although the percentage of patients who died or experienced worsening HF at 14 days was lower and the percentage of patients with myocardial ischaemia was higher in the levosimendan group, the differences did not reach statistical significance.[ 41 ] Overall, the percentage of patients meeting the primary composite endpoint criteria at 14 days was lower, albeit not significantly, with levosimendan (21.2% versus 26.2%).[ 41 ] At 6 months, the non-significant trends for death and worsening HF were supplemented by a significant trend for a

also in 98,063 other papers